Pharmaceutical Products
NME (New Molecule Entity) products
- JP-1366: Erosive Esophagitis(Market), Gastric Ulcer(P3), Prevention for NSAIDs induced Pus(P3)- JP-2266: Type II Diabetes Mellitus(P2) - JPI-547: Ovarian Cancer(P2), Pancreatic Cancer(P2) - JPI-289: Myocardial Infarction(P2) IMD (Incrementally Modified Drug) products
- JLP-2206: Hyperlipidemia (Discovery)- JLP-2302: EE (Discovery) - JLP-2004: Pain (P1) - JLP-2103: Asthma / Rhinitis(Market) - JLP-2008: Diabetes(Market) - ATB-101: Hypertension + Diabetes (P3) |
Technologies
 Synthesis of Active Pharmaceutical Ingredients (APIs)Formulation Technology |
| First Name * | |
| Last Name * | |
| Title * | |
| Company * | |
| Address 1 | |
| Address 2 | |
| City | |
| Country | |
| Postal Code | |
| E-mail Address * | |
| Phone * | |
| Fax | |
| Summary Description of Potential Opportunity * (2,000 character's limit) |
|
| Type of Business * | |
| * Required Field Submit Cancel |
|
